Medical Science News

RSS

What is the structure and function of SARS-CoV-2’s D614G spike mutation?

A team of researchers use a computational approach to integrate available data D614G SARS-CoV-2 spike mutation, exploring its structure and molecular mechanisms.

2 Feb 2021

Zinc supplementation bolsters repurposed antivirals against SARS-CoV-2

A new preprint reports the efficacy of two repurposed drugs that could be useful against SARS-CoV-2 when supplemented with zinc.

2 Feb 2021

Pfizer-BioNTech vaccine shows promise against new SARS-CoV-2 variants

A team of researchers in the U.S. studied the Pfizer-BioNTech vaccine candidate - currently being rolled out in many parts of the world to high-risk individuals - to see if it still holds up against mutant strains of the virus and yielded encouraging results.

2 Feb 2021

ACE2 agonist C21 relieves respiratory difficulty in COVID-19

A new study describes a pilot study on the efficacy of a molecule called C21, which enhances the activity of the angiotensin-converting enzyme 2 (ACE2), the host cell receptor that facilitates viral entry.

2 Feb 2021

Antiviral compound GC-376 shows efficacy against SARS-CoV-2 in vivo

Over the past months, many potential antivirals against SARS-CoV-2 have been identified as deserving further development to target several viral proteins. A new study deals with one such molecule, the viral main protease (Mpro) inhibitor GC-376, and describes its efficacy in inhibiting virus-host interaction.

2 Feb 2021

Lower diagnostic threshold for fever in older people may help detect COVID-19 cases earlier

Researchers have explored heritable factors, age and body mass on temperature variation between humans. One notable finding is that the current threshold for detecting fever in older adults may be too high, precluding the ability to detect COVID-19 early on

2 Feb 2021

Researchers develop new modeling to map SARS-CoV-2 transmission dynamics in UK

Using a modified version of the susceptible-infectious-recovered (SIR) model to include effects of prevention measures, researchers show patterns in the increase and decrease of coronavirus disease 2019 (COVID-19) cases in the UK.

2 Feb 2021

New portable device produces high-resolution 3D images of human skin within 10 minutes

A team from Nanyang Technological University, Singapore (NTU Singapore) has developed a portable device that produces high-resolution 3D images of human skin within 10 minutes.

2 Feb 2021

Could ultra-low dose radiotherapy treat COVID-19-related pneumonia?

Researchers at the Department of Radiation Oncology, La Milagrosa Hospital, GenesisCare, Madrid, Spain, showed the potential benefit of treating COVID-19 pneumonia with ultra-low doses of radiotherapy.

2 Feb 2021

Differences in immune response to SARS-CoV-2 determine disease severity, study finds

Researchers investigate host responses to SARS-CoV-2, respiratory syncytial virus (RSV), and influenza virus (IV) in the nasal mucosa in children and adults.

2 Feb 2021

Johnson & Johnson SARS-CoV-2 vaccine shows promise in clinical trials

A new study shows that a single immunization with a low dose of the Ad26.COV2.S vaccine – also known as the ‘Johnson & Johnson vaccine’ – effectively protected against SARS-CoV-2 challenge in rhesus macaques.

2 Feb 2021

Albumin: The Natural Choice for Diagnostic Tests

The availability of established diagnostic kits has enabled researchers to plug-and-play in the design of COVID-19 diagnostics. Such technologies took decades to optimize, but they are now playing an important role in identifying and managing the spread of COVID-19. Recombumin® provides an enhanced solution as part of this toolbox for dealing with this disease

From Albumedix Ltd. 2 Feb 2021

Albumedix submits Drug Master Files for its products in Japan

Albumedix Ltd. (‘Albumedix’), the world leader in recombinant human albumin (rHA), announced today the submission of Drug Master Files (DMFs) to the Pharmaceutical and Medical Device Agency (PMDA) in Japan.

From Albumedix Ltd. 2 Feb 2021

Albumedix enters into collaboration agreement with Cell and Gene Therapy Catapult

Albumedix Ltd. (‘Albumedix’), an enabler of advanced therapies and the world leader in recombinant human albumin (rAlb), announced today that they have entered into a collaboration agreement with Cell and Gene Therapy Catapult (CGT Catapult) to investigate the use of Albumedix´ proprietary albumin-based solutions for advanced therapy applications, including viral vectors manufacturing.

From Albumedix Ltd. 2 Feb 2021

Synthetic biology can help create complex embryo

Richard Feynman, one of the most respected physicists of the twentieth century, said "What I cannot create, I do not understand". Not surprisingly, many physicists and mathematicians have observed fundamental biological processes with the aim of precisely identifying the minimum ingredients that could generate them. One such example are the patterns of nature observed by Alan Turing.

2 Feb 2021

Research shows a promising alternative to personalized deep brain stimulation

Millions of patients suffering from neurological and mental disorders such as depression, addiction, and chronic pain are treatment-resistant. In fact, about 30% of all major depression patients do not respond at all to any medication or psychotherapy.

2 Feb 2021